ArriVent Biopharma Inc

On March 27, 2024, Dr. Jallal notified our board of directors of her decision to resign from our board of directors and the compensation committee and the nominating and corporate governance committee, effective March 28, 2024. Dr. Jallal’s decision to resign was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

On March 28, 2024, we notified the Nasdaq Stock Market (“Nasdaq”) of Dr. Jallal’s resignation from the board of directors and that because such resignation, the compensation committee (the “Compensation Committee”) of our board of directors will have only one member, and the registrant will no longer comply with Nasdaq Listing Rule 5605(d)(2), which requires companies with securities listed on Nasdaq to have a compensation committee composed of at least two directors. In accordance with Nasdaq Listing Rule 5605(d)(4), we have an automatic cure period in order to regain compliance. We expect to regain compliance with such rule by filling the vacancy on the Compensation Committee caused by Dr. Jallal’s resignation with an independent director who satisfies the applicable requirements of the Nasdaq Listing Rules prior to the expiration of the cure period provided under Nasdaq Listing Rule 5605.

Rule 10b5-1 Trading Plans

During the fiscal quarter ended December 31, 2023, none of our directors or executive officers adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K.

Item 9C. Dis